Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 18;13(6):1372.
doi: 10.3390/cancers13061372.

Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer

Patricia Le  1 , Giulia Romano  1 , Patrick Nana-Sinkam  1 , Mario Acunzo  1
Affiliations
Review

Non-Coding RNAs in Cancer Diagnosis and Therapy: Focus on Lung Cancer

Patricia Le et al. Cancers (Basel). .

Abstract

Over the last several decades, clinical evaluation and treatment of lung cancers have largely improved with the classification of genetic drivers of the disease, such as EGFR, ALK, and ROS1. There are numerous regulatory factors that exert cellular control over key oncogenic pathways involved in lung cancers. In particular, non-coding RNAs (ncRNAs) have a diversity of regulatory roles in lung cancers such that they have been shown to be involved in inducing proliferation, suppressing apoptotic pathways, increasing metastatic potential of cancer cells, and acquiring drug resistance. The dysregulation of various ncRNAs in human cancers has prompted preclinical studies examining the therapeutic potential of restoring and/or inhibiting these ncRNAs. Furthermore, ncRNAs demonstrate tissue-specific expression in addition to high stability within biological fluids. This makes them excellent candidates as cancer biomarkers. This review aims to discuss the relevance of ncRNAs in cancer pathology, diagnosis, and therapy, with a focus on lung cancer.

Keywords: cancer diagnosis; cancer therapy; lung cancer; non-coding RNA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Non-coding RNA (ncRNA) research milestones [2,4,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35].
Figure 2
Figure 2
Biogenesis of select ncRNAs.
Figure 3
Figure 3
ncRNAs in lung cancer.
See this image and copyright information in PMC

References

    1. Deveson I.W., Hardwick S.A., Mercer T.R., Mattick J.S. The Dimensions, Dynamics, and Relevance of the Mammalian Noncoding Transcriptome. Trends Genet. 2017;33:464–478. doi: 10.1016/j.tig.2017.04.004. - DOI - PubMed
    1. Mercer T.R., Gerhardt D.J., Dinger M.E., Crawford J., Trapnell C., Jeddeloh J.A., Mattick J.S., Rinn J.L. Targeted RNA sequencing reveals the deep complexity of the human transcriptome. Nat. Biotechnol. 2011;30:99–104. doi: 10.1038/nbt.2024. - DOI - PMC - PubMed
    1. Kapranov P., St Laurent G. Dark Matter RNA: Existence, Function, and Controversy. Front. Genet. 2012;3:60. doi: 10.3389/fgene.2012.00060. - DOI - PMC - PubMed
    1. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Devon K., Dewar K., Doyle M., FitzHugh W., et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921. doi: 10.1038/35057062. - DOI - PubMed
    1. Johnson J.M., Edwards S., Shoemaker D., Schadt E.E. Dark matter in the genome: Evidence of widespread transcription detected by microarray tiling experiments. Trends Genet. 2005;21:93–102. doi: 10.1016/j.tig.2004.12.009. - DOI - PubMed

LinkOut - more resources